Article Versions Notes

Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, et al. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers. 2022; 14(7):1751. https://doi.org/10.3390/cancers14071751

Descourt, Renaud, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loïck Galland, and et al. 2022. "Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study" Cancers 14, no. 7: 1751. https://doi.org/10.3390/cancers14071751

Descourt, R., Pérol, M., Rousseau-Bussac, G., Planchard, D., Mennecier, B., Wislez, M., Cadranel, J., Cortot, A. B., Guisier, F., Galland, L., Do, P., Schott, R., Dansin, É., Arrondeau, J., Auliac, J.-B., Geier, M., & Chouaïd, C. (2022). Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers, 14(7), 1751. https://doi.org/10.3390/cancers14071751